MUC16 and ovarian cancer: Although their study had a small sample size, Riedinger et al. (31) in a small sample size study in advanced ovarian cancer, NACT used to ccompletely removed macroscopic disease which significantly improved the prognosis of patients with preoperative CA-125 ≤ 20 U/ml.